Hepatocellular carcinoma: gardening strategies and bridges to transplantation.
BACKGROUND
Survival after liver transplantation for early hepatocellular carcinoma (HCC) is worsened by the increasing dropout rate while waiting for a donor.


OBJECTIVE
To assess the cost effectiveness of adjuvant therapy while waiting for liver transplantation in HCC patients.


METHODS
Using a Markov model, a hypothetical cohort of cirrhotic patients with early HCC was considered for: (1) adjuvant treatment-resection was limited to Child-Pugh's A patients with single tumours, and percutaneous treatment was considered for Child-Pugh's A and B patients with single tumours unsuitable for resection or with up to three nodules < 3 cm; and (2) standard management. Length of waiting time ranged from six to 24 months.


RESULTS
Surgical resection increased the transplantation rate (>10%) and provided gains in life expectancy of 4.8-6.1 months with an acceptable cost (US dollars 40,000/ year of life gained) for waiting lists > or = 1 year whereas it was not cost effective (US dollars 74,000/life of year gained) for shorter waiting times or high dropout rate scenarios. Percutaneous treatment increased life expectancy by 5.2-6.7 months with a marginal cost of approximately US dollars 20,000/year of life gained in all cases, remaining cost effective for all waiting times.


CONCLUSIONS
Adjuvant therapies for HCC while waiting for liver transplantation provide moderate gains in life expectancy and are cost effective for waiting lists of one year or more. For shorter waiting times, only percutaneous treatment confers a relevant survival advantage.
Gores
Gregory J
GJ
Transplant Center, Mayo Clinic, Rochester, MN, USA.
D006528:Carcinoma, Hepatocellular / Q000188:drug therapy / Q000601:surgery / Q000628:therapy*; D017024:Chemotherapy, Adjuvant / Q000191:economics*; D003362:Cost-Benefit Analysis; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy / Q000601:surgery / Q000628:therapy*; D016031:Liver Transplantation; D014850:Waiting Lists